Manufacturer of Lenvatinib

Lenvatinib is an anticancer drug used to treat certain types of thyroid, kidney, liver, and endometrial cancer. The FDA first approved lenvatinib developed by Eisai Company (Japanese Eisai Co., Ltd.) in February 2015 as a multiple kinase inhibitor targeting VEGFR1, VEGFR2 and VEGFR3 kinases.

Lenvatinib is classified as an oral multi-receptor tyrosine kinase (RTK) inhibitor that blocks certain proteins that promote cancer cell growth and is also known as a vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) inhibitor. It blocks signals to help slow the growth of new blood vessels (angiogenesis) in existing blood vessels that support tumor growth. Abnormal angiogenesis can occur in cancer, degenerative eye diseases, and other medical conditions involving inflammation. Lenvatinib is also considered an oral targeted therapy, rather than a chemotherapy drug.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of lenvatinib are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be RMB 800 per box (the price may fluctuate due to exchange rate effects).